Sonia Habibian1, Keith Ahamad, Mark McLean, Maria Eugenia Socias. 1. British Columbia Centre on Substance Use, Vancouver, BC, Canada (SH, KA, MM, MES); Department of Family Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada (SH, KA, MM); Vancouver Detox, Vancouver Coastal Health, Vancouver, BC, Canada (SH, KA, MM); Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada (MES).
Abstract
BACKGROUND: Gamma-hydroxybutyrate (GHB)-a GABA-B agonist-can lead to a use disorder, and a withdrawal syndrome similar to that of alcohol. At present, evidence is lacking for how to best manage GHB withdrawal, and often clinicians rely on alcohol withdrawal management approaches, using medications like benzodiazepines (BZD). However, BZD doses needed to control GHB withdrawal symptoms are typically much higher than those required for alcohol, posing significant safety risks. Novel approaches include the use of baclofen as an adjunct to BZD, allowing reductions in BZD requirements. While the use of baclofen as monotherapy may result in even greater risk reductions, research to support this approach is limited. CASE: We present a case of a 26-year-old female with severe GHB use disorder and history of severe withdrawal symptoms, whose withdrawal was successfully, managed using baclofen alone. CONCLUSION: In keeping with other case reports, baclofen appears to have potential to be used in the management of GHB withdrawal. Here, we presented a case of severe GHB withdrawal which was managed solely by baclofen. Clinical research is needed to evaluate baclofen's potential as a standalone treatment for GHB withdrawal.
BACKGROUND:Gamma-hydroxybutyrate (GHB)-a GABA-B agonist-can lead to a use disorder, and a withdrawal syndrome similar to that of alcohol. At present, evidence is lacking for how to best manage GHB withdrawal, and often clinicians rely on alcohol withdrawal management approaches, using medications like benzodiazepines (BZD). However, BZD doses needed to control GHB withdrawal symptoms are typically much higher than those required for alcohol, posing significant safety risks. Novel approaches include the use of baclofen as an adjunct to BZD, allowing reductions in BZD requirements. While the use of baclofen as monotherapy may result in even greater risk reductions, research to support this approach is limited. CASE: We present a case of a 26-year-old female with severe GHB use disorder and history of severe withdrawal symptoms, whose withdrawal was successfully, managed using baclofen alone. CONCLUSION: In keeping with other case reports, baclofen appears to have potential to be used in the management of GHB withdrawal. Here, we presented a case of severe GHB withdrawal which was managed solely by baclofen. Clinical research is needed to evaluate baclofen's potential as a standalone treatment for GHB withdrawal.
Authors: Amy K Goodwin; Barbara J Kaminski; Roland R Griffiths; Nancy A Ator; Elise M Weerts Journal: Drug Alcohol Depend Date: 2010-11-26 Impact factor: 4.492
Authors: Klemens Kaupmann; John F Cryan; Petrine Wellendorph; Cedric Mombereau; Gilles Sansig; Klaus Klebs; Markus Schmutz; Wolfgang Froestl; Herman van der Putten; Johannes Mosbacher; Hans Bräuner-Osborne; Peter Waldmeier; Bernhard Bettler Journal: Eur J Neurosci Date: 2003-11 Impact factor: 3.386
Authors: Casper J H Wolf; Harmen Beurmanjer; Boukje A G Dijkstra; Alexander C Geerlings; Marcia Spoelder; Judith R Homberg; Arnt F A Schellekens Journal: J Clin Med Date: 2021-05-26 Impact factor: 4.241